

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-45. (Canceled).

46. (Previously Presented) A method for treating a wound and/or improving wound healing ~~wherein comprising administering~~ a therapeutically effective amount of a pharmaceutical composition comprising a peptide derived from amino acid 12 to amino acid 40 of human lactoferrin ~~that inhibits a pro-inflammatory cytokine is administered to a patient in need of said treatment thereof, wherein:~~

said peptide inhibits a pro-inflammatory cytokine;

said peptide comprises ²⁰Cys-Phe-X₁-X₂-X₃-X₄-X₅-X₆-X₇-Lys-Val-Arg³¹ (SEQ ID NO: 99), wherein X₁ is Gln or Ala; X₂ is Trp or Leu; X₃ is Gln, Lys, Orn, Ala, or Nle; X₄ is Arg, Lys, or Ala; X₅ is Asn, Orn, Ala, or Nle; X₆ is Met or Leu; and X₇ is Arg or Lys; and

said peptide is selected from the group consisting of SEQ ID NOS: 2-5, 8, 31-37, 47, 49, 51, 63, 65, 67, 70, 72-74, 80-83, and 87-97.

47-48. (Canceled).

49. (New) The method of claim 46, wherein said wound is related to posttraumatic tissue injury.

50. (New) The method of claim 49, wherein said posttraumatic tissue injury is caused by surgery.

51. (New) The method of claim 46, wherein said wound is related to thermic injury.

52. (New) The method of claim 46, wherein said wound is a result of a metabolic process due to reduced nutritional supply.

53. (New) The method of claim 52, wherein said wound is a diabetic ulcer, a leg ulcer, a decubitus ulcer or a gastric ulcer.

54. (New) The method of claim 46, wherein said wound is a result of exposure to a toxic compound.

55. (New) The method of claim 46, wherein said pharmaceutical composition is locally administered.

56. (New) The method of claim 46, wherein said pharmaceutical composition is systemically administered.